Bevacizumab Adoption Tied to Use by Peers
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
Brain Cancer
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
One-Third of Glioblastomas Had Molecular Changes at Recurrence
Repeat biopsies may be needed prior to patient inclusion in targeted-therapy trials.
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups.
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
How to Help Patients With Cancer Find Trustworthy Information Online
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.
Gender Bias in Oncology: Q&A With Dr Narjust Duma
Women are less likely to be introduced by their professional title and most likely to be introduced by first name.
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Next post in General Oncology
